Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease

Maurits E. L. Arbouw (1, 2, 3) , Kris L. L. Movig (3) , Toine C. G. Egberts (1, 2) , Petra J. E. Poels (4) , Jeroen P. P. Vugt (5) , Judith A. M. Wessels (6) , R. J. H. M. Straaten (6) , Cees Neef (7) , Henk-Jan Guchelaar (6)

1 Department of Clinical Pharmacy
2 Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science
3 Department of Clinical Pharmacy
4 Department of Neurology
5 Department of Neurology
6 Department of Clinical Pharmacy and Toxicology
7 Department of Clinical Pharmacy and Toxicology

Mots clés: Determinants; Discontinuation; Dopamine agonists; Dopamine receptors; Parkinson's disease; Pharmacogenetics; Pramipexole; Ropinirole

Maurits E. L. Arbouw, Kris L. L. Movig, Toine C. G. Egberts, Petra J. E. Poels, Jeroen P. P. Vugt, et al.. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. European Journal of Clinical Pharmacology, 2009, 65 (12), pp.1245-1251. ⟨10.1007/s00228-009-0708-6⟩. ⟨hal-00534986⟩